ライフサイエンスコーパス: recent myocardial infarction

1 the Duke coronary artery disease index, and recent myocardial infarction.

2 implantable defibrillators in patients with recent myocardial infarction.

3 l mortality and sudden death in survivors of recent myocardial infarction.

4 (VF) episodes, often occurs in patients with recent myocardial infarction.

5 captopril were assessed in a canine model of recent myocardial infarction.

6 either chronic coronary artery disease or a recent myocardial infarction.

7 with stable atherosclerosis and by 23% after recent myocardial infarction.

8 mic cardiovascular events in patients with a recent myocardial infarction.

9 dvanced chronic coronary artery disease or a recent myocardial infarction.

10 e were heart failure, diabetes mellitus, and recent myocardial infarction.

11 age per 10-year increase (1.36 [1.33-1.39]), recent myocardial infarction (1.24 [1.08-1.42]), and low

12 studied three groups: (1) 715 patients with recent myocardial infarction; (2) 274 healthy persons ag

13 ardiac regeneration therapy in patients with recent myocardial infarction, a recently published meta-

14 for transplantation or who have sustained a recent myocardial infarction also raises concerns.

15 In patients with recent myocardial infarction and multivessel coronary ar

16 rnational multicenter study of patients with recent myocardial infarction and multivessel coronary ar

17 In 8 pigs with recent myocardial infarction and variable degrees of rep

18 York Heart Association class, lung disease, recent myocardial infarction, and prior cardiovascular s

19 sease, active endocarditis, unstable angina, recent myocardial infarction, and pulmonary hypertension

20 aft surgery, a history of hypertension, or a recent myocardial infarction; and less likely to be curr

21 Cell uptake determinants in humans with recent myocardial infarction are not defined.

22 clusion criteria included heart failure or a recent myocardial infarction, as well as having a beta-b

23 mented stable CAD without heart failure or a recent myocardial infarction, beta-blockers were associa

24 entially regenerative cellular treatments to recent myocardial infarction borders is feasible with an

25 Among patients with recent myocardial infarction, both treated and untreated

26 sk of cardiovascular events in patients with recent myocardial infarction, but evidence of such a ris

27 Patients with recent myocardial infarction; class III or IV heart fail

28 Among patients with a recent myocardial infarction, colchicine at a dose of 0.

29 In this cohort study of patients with recent myocardial infarction, coronary atherosclerotic p

30 In patients with a recent myocardial infarction, empagliflozin was associat

31 th population-based cohorts, patients with a recent myocardial infarction had a higher annual inciden

32 Major predictors of use included recent myocardial infarction; hypertension; worse angina

33 High-risk characteristics included recent myocardial infarction in 41.4% of the cases, angi

34 tested the efficacy of beta blockers after a recent myocardial infarction in patients without reduced

35 s delivered via an intracoronary route after recent myocardial infarction is related to left ventricu

36 age, 68 y; 93% male), and 52 patients had a recent myocardial infarction (median age, 65 y; 83% male

37 pressed left ventricular (LV) function after recent myocardial infarction (MI) and in a subpopulation

38 ure cardiovascular events in patients with a recent myocardial infarction (MI) and patients with susp

39 s study was to determine, in patients with a recent myocardial infarction (MI) and residual wall moti

40 We aimed to assess the impact of recent myocardial infarction (MI) on outcomes after subs

41 eatment with a DOAC for AF or VTE, without a recent myocardial infarction (MI) or history of heart va

42 detection of myocardial edema resulting from recent myocardial infarction (MI) or intervention.

43 was 3.77% but was only 1.35% in PCI without recent myocardial infarction (MI) within one week (p < 0

44 (CHAOS II), the cases were 249 patients with recent myocardial infarction (MI), and a further 183 unr

45 reased risk for mortality in patients with a recent myocardial infarction (MI).

46 rly cardiac events (<1 year) in women with a recent myocardial infarction (MI).

47 e events are more effective in patients with recent myocardial infarction, multiple myocardial infarc

48 (odds ratio, 2.33 [95% CI, 1.66-3.28]), and recent myocardial infarction (odds ratio, 8.38 [95% CI,

49 l flutter or fibrillation, pacemaker rhythm, recent myocardial infarction or bypass surgery, and pati

50 Patients who presented with acute or recent myocardial infarction or cardiogenic shock were e

51 event cardiovascular events in patients with recent myocardial infarction or heart failure.

52 t these trials did not include patients with recent myocardial infarctions or unstable angina.

53 Recurrent coronary events in patients with recent myocardial infarction remain a major clinical pro

54 eduction of ischemic events in patients with recent myocardial infarction, stroke, or peripheral arte

55 criteria allowed enrollment of patients with recent myocardial infarction, total occlusions, bifurcat

56 pective natural history study, patients with recent myocardial infarction underwent 3-vessel coronary

57 significantly higher in those patients with recent myocardial infarction, unstable angina, and depre

58 Patients with a recent myocardial infarction were at greater risk of par

59 57+/-10 years) who had ES associated with a recent myocardial infarction were separated into 2 group

60 ients with chronic ischemic heart disease or recent myocardial infarction who exhibit marked regional

61 al cardiac arrhythmias among subjects with a recent myocardial infarction who had been advised to con

62 n the risk stratification of patients with a recent myocardial infarction who receive conventional th